5 healthcare transactions with the highest price tags in 2014

There have been 46 healthcare deals with prices exceeding $1 billion so far this year. Although those transactions only make up 4 percent of the 1,161 healthcare mergers and acquisitions that have taken place this year, they make up 85 percent of total spending, according to a recent report from Irving Levin Associates.

Advertisement

Here are the five deals with the highest price tags so far in 2014.  

1.  Troy Hills, N.J.-based pharmaceutical company Actavis paid $66 billion to acquire fellow pharmaceutical company Irvine, Calif.-based Allergan, Inc.

2.  Minneapolis-based Medtronic, a medical device manufacture, paid $42.9 billion to acquire Dublin-based Covidien.

3. Actavis paid $25 billion to acquire Forest Labs, a pharmaceutical company based in New York City.

4. White House Station, N.J.-based Merck paid $17 billion to acquire Sigma-Aldrich Corp., a life science and technology company based in St. Louis.

5. Basel, Switzerland-based pharmaceutical company Novartis paid $16 billion to acquire Brentford, England- based GlaxoSmithKline’s oncology business.

More articles on healthcare industry transactions:

Boston Medical Center, Tufts begin merger talks
Tenet ends bid to acquire 5 Connecticut hospitals
Breaking down the 5 most interesting hospital M&A deals of the year

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Transactions & Valuation Issues

Advertisement

Comments are closed.